Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

NICE turns down CDF drug Adcetris in draft guidance

Takeda’s treatment for Hodgkin’s lymphoma not seen to be cost-effective

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

What kind of customer data are you getting?

How to collect the proper data to discover how to act next.

Anthill Agency

- PMLiVE

Parexel adds four to senior leadership team

Appoints David Godwin, Michelle Graham, Sy Pretorius and Joshua Schultz

- PMLiVE

Allergies and asthma

Reframing the conversation from disease burden to prevention and health promotion

Products as portfolios: positioning immuno-oncology products

The last few years have seen a huge proliferation in the number of products entering the oncology space, with a lot more currently being investigated in clinical trials. Effective positioning...

Blue Latitude Health

- PMLiVE

Merck & Co gets EU green light for hep C drug Zepatier

Will enter a market currently dominated by Gilead's Harvoni and Sovaldi

- PMLiVE

NICE swayed by extra data on Amgen’s Imlygic

Cost effectiveness watchdog backs immunotherapy in final draft guidance

AstraZeneca AZ global R&D corporate HQ

AZ’s selumetinib stumbles at last fence in lung cancer

Phase III trial shows failure to improve patient survival rates

- PMLiVE

Sigma-Tau Pharmaceuticals appoints CEO

Interim CEO Michael Minarich takes up the post in a permanent capacity

- PMLiVE

Is your multichannel having the desired impact on both your customer and business?

The critical role of multichannel in delivering a differentiated customer experience and tangible business results

Astellas launches digital health investment company

Will look for firms that focus on patient outcomes and offer pharma synergies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links